Original Article
Subject Categories: Vaccine Technology
Molecular Therapy (2007) 15, 203–210. doi:10.1038/sj.mt.6300034
Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax
Michael J McConnell1, Philip C Hanna1 and Michael J Imperiale1
1Department of Microbiology and Immunology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA
Correspondence: Michael J Imperiale, University of Michigan Medical School, 6304 Cancer Center, 1500 E. Medical Center Dr, Ann Arbor, Michigan 48109-0942, USA. E-mail: imperial@umich.edu
Received 21 July 2006; Accepted 18 August 2006.
Abstract
Prime-boost vaccination using plasmid DNA and replication-defective adenovirus vectors has emerged as a highly effective strategy for vaccinating against viral pathogens. However, its ability to provide protection against bacterial disease has never been assessed. Here we evaluate prime-boost vaccination approaches for immunizing against anthrax. We show that mice primed with DNA and boosted with an adenovirus vector, both expressing domain four of Bacillus anthracis protective antigen (PA), have higher antibody and toxin-neutralizing titers than mice immunized with either single modality alone. DNA-primed/adenovirus–boosted mice also had significantly higher antibody and toxin-neutralizing titers than mice immunized with Anthrax Vaccine Adsorbed. High levels of antigen-specific interferon-gamma-secreting cells were present in vaccinated mice indicating that a cell-mediated immune response had also been stimulated. Both DNA-primed/adenovirus–boosted and adenovirus-primed/adenovirus–boosted mice were fully protected from Sterne strain spore challenge. We also show that a single injection with an adenovirus vector-expressing domain four of PA can provide partial protection from spore challenge 2 weeks after immunization and full protection 3 weeks after immunization. These results demonstrate that adenovirus-based prime-boost vaccination can provide rapid protection from anthrax and that this approach may be an effective strategy for immunizing against bacterial as well as viral pathogens.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Myelin managementNature Medicine News and Views (01 Jan 2003)
A dominant-negative therapy for anthraxNature Medicine News and Views (01 Jun 2001)
See all 8 matches for News And ViewsRESEARCH
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseNature Medicine Letter (01 Jun 2005)
Genetic Vaccines for Anthrax Based on Recombinant Adeno-associated Virus VectorsMolecular Therapy Original Article
See all 36 matches for Research
